

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : TAHRI, Abdellah; WIGERINCK, Piet Tom Bert Paul
Serial No. : Not Assigned Art Unit: TBA
Filed : February 10, 2005 Examiner: TBA
For : BROADSPECTRUM SUBSTITUTED OXINDOLE SULFONAMIDE
HIV PROTEASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the

above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed

herewith EXCEPT THAT:

and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached is a copy of a search report from corresponding patent application PCT/EP03/50379, which is listed on the attached Submission Under MPEP 609 D.

10/524451
BT01 AGO PCT/P 10 FEB 2005

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TIP0043USNP/AGK. This form is submitted in triplicate.

Respectfully submitted,



Alana G. Kriegsman
Reg. No. 41,747
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: February 10, 2005

PTO/SB/08A (08-00)
1 0 FEB 2005

Express Mail Label No. EV488941470 US

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	107524451
Filing Date	February 10, 2005
First Named Inventor	TAHRI, Abdellah
Group Art Unit	
Examiner Name	
Attorney Docket Number	TIP-0043 USPCT

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		EP	0499299	B1	Sterling Winthrop Inc.	08-19-1992		
		EP	0499299	A2	Sterling Winthrop Inc.	08-19-1992		
		EP	0721331	B1	AstraZeneca, AB.	07/17/1996		
		WO	95/06030	A1	G.D. SEARLE & CO.	03-02-1995		
		WO	95/09615	A1	AstraZeneca, AB.	04-13-1996		
		WO	96/22287	A1	G.D. SEARLE & CO.	07-25-1996		
		WO	96/28418	A1	G.D. SEARLE & CO.	09-19-1996		
		WO	96/28463	A1	G.D. SEARLE & CO.	09-19-1996		
		WO	96/28464	A1	G.D. SEARLE & CO.	09-19-1996		
		WO	96/28465	A1	G.D. SEARLE & CO.	09-19-1996		
		WO	97/18205	A1	G.D. SEARLE & CO.	05-22-1997		
		WO	99/67254	A2	The United States of America represented by The Secretary, Department of Health and Human Services	12-29-1999		
		WO	99/33795	A1	VERTEX PHARMACEUTICALS INC.	07-08-1999		
		WO	99/33815	A1	VERTEX PHARMACEUTICALS INC.	07-08-1999		
		WO	99/33792	A2	VERTEX PHARMACEUTICALS INC.	07-08-1999		
		WO	99/33793	A2	VERTEX PHARMACEUTICALS INC.	07-08-1999		
		WO	94/05263	A1	JANSSEN PHARMACEUTICA N.V.	03-17-1994		
		WO	99/67417	A2	The United States of America represented by The Secretary, Department of Health and Human Services	12-29-1999		
		WO	98/42318	A1	JANSSEN PHARMACEUTICA N.V.	10-01-1998		
		WO	97/44014	A1	JANSSEN PHARMACEUTICA N.V.	11-27-1997		
		WO	01/72708	A2	COR THERAPEUTICS INC.	10/04/2001		
		WO	99/65870	A2	VERTEX PHARMACEUTICALS INC.	12/23/1999		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Express Mail Label No. EV488941470 US

SUBMISSION UNDER MPEP 609 D	Application Number	10752442
	Filing Date	February 10, 2005
	First Named Inventor	TAHRI, Abdellah
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	TIP0043 US PCT

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--